These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 35881304)

  • 1. Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies.
    Cohen HP; Hachaichi S; Bodenmueller W; Kvien TK; Danese S; Blauvelt A
    BioDrugs; 2022 Sep; 36(5):625-637. PubMed ID: 35881304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective.
    Kurki P; Barry S; Bourges I; Tsantili P; Wolff-Holz E
    Drugs; 2021 Nov; 81(16):1881-1896. PubMed ID: 34596876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes.
    Cohen HP; Blauvelt A; Rifkin RM; Danese S; Gokhale SB; Woollett G
    Drugs; 2018 Mar; 78(4):463-478. PubMed ID: 29500555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab.
    Feagan BG; Lam G; Ma C; Lichtenstein GR
    Aliment Pharmacol Ther; 2019 Jan; 49(1):31-40. PubMed ID: 30411382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.
    McKinnon RA; Cook M; Liauw W; Marabani M; Marschner IC; Packer NH; Prins JB
    BioDrugs; 2018 Feb; 32(1):27-52. PubMed ID: 29344876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety outcomes when switching between biosimilars and reference biologics: A systematic review and meta-analysis.
    Herndon TM; Ausin C; Brahme NN; Schrieber SJ; Luo M; Andrada FC; Kim C; Sun W; Zhou L; Grosser S; Yim S; Ricci MS
    PLoS One; 2023; 18(10):e0292231. PubMed ID: 37788264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioequivalence of Biosimilar Tumor Necrosis Factor-α Inhibitors Compared With Their Reference Biologics: A Systematic Review.
    Chingcuanco F; Segal JB; Kim SC; Alexander GC
    Ann Intern Med; 2016 Oct; 165(8):565-574. PubMed ID: 27479870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review.
    Tieu C; Lucas EJ; DePaola M; Rosman L; Alexander GC
    PLoS One; 2018; 13(4):e0195012. PubMed ID: 29668697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching Among Biosimilars: A Review of Clinical Evidence.
    Allocati E; Godman B; Gobbi M; Garattini S; Banzi R
    Front Pharmacol; 2022; 13():917814. PubMed ID: 36091837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.
    Inotai A; Prins CPJ; Csanádi M; Vitezic D; Codreanu C; Kaló Z
    Expert Opin Biol Ther; 2017 Aug; 17(8):915-926. PubMed ID: 28650704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world switching and discontinuation outcomes of infliximab biosimilars in patients with rheumatoid arthritis: A scoping review.
    Yin Y; McDermott C; Lockhart C
    J Manag Care Spec Pharm; 2023 Sep; 29(9):985-998. PubMed ID: 37610110
    [No Abstract]   [Full Text] [Related]  

  • 13. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
    Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
    Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physicians' perceptions of the uptake of biosimilars: a systematic review.
    Sarnola K; Merikoski M; Jyrkkä J; Hämeen-Anttila K
    BMJ Open; 2020 May; 10(5):e034183. PubMed ID: 32371511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars in ulcerative colitis: When and for who?
    Ilias A; Gonczi L; Kurti Z; Lakatos PL
    Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars.
    Desai RJ; Kim SC; Curtis JR; Bosco JLF; Eichelberger B; Barr CE; Lockhart CM; Bradbury BD; Clewell J; Cohen HP; Gagne JJ;
    Pharmacoepidemiol Drug Saf; 2020 Jul; 29(7):757-769. PubMed ID: 31298463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies.
    Numan S; Faccin F
    Adv Ther; 2018 Sep; 35(9):1295-1332. PubMed ID: 30084060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of Cancer: A Systematic Review and Meta-analysis.
    Bloomfield D; D'Andrea E; Nagar S; Kesselheim A
    JAMA Oncol; 2022 Apr; 8(4):537-545. PubMed ID: 35113135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review.
    Barbier L; Ebbers HC; Declerck P; Simoens S; Vulto AG; Huys I
    Clin Pharmacol Ther; 2020 Oct; 108(4):734-755. PubMed ID: 32236956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies.
    Odinet JS; Day CE; Cruz JL; Heindel GA
    J Manag Care Spec Pharm; 2018 Oct; 24(10):952-959. PubMed ID: 30247100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.